Matt Simmons ๐Ÿ’Š (@matthewhsimmons) 's Twitter Profile
Matt Simmons ๐Ÿ’Š

@matthewhsimmons

Oncology Strategy Lead @IQVIA_Biotech. Opinions my own.

ID: 400002857

linkhttps://www.linkedin.com/in/simmonsmatt/ calendar_today28-10-2011 11:02:29

2,2K Tweet

442 Takipรงi

332 Takip Edilen

Matt Simmons ๐Ÿ’Š (@matthewhsimmons) 's Twitter Profile Photo

"In Phase I trials, #AI-discovered molecules are substantially more successful than historic industry averages..." sciencedirect.com/science/articlโ€ฆ

"In Phase I trials, #AI-discovered molecules are substantially more successful than historic industry averages..."

sciencedirect.com/science/articlโ€ฆ
Matt Simmons ๐Ÿ’Š (@matthewhsimmons) 's Twitter Profile Photo

Although careful consideration is necessary to determine which #clinicaltrials in #oncology are well suited for inclusion of pragmatic design features, there is growing momentum to simplify, broaden access and increase generalizability of study data.... ascopubs.org/doi/10.1200/EDโ€ฆ

Matt Simmons ๐Ÿ’Š (@matthewhsimmons) 's Twitter Profile Photo

Noteworthy advances in oncology R&D shared during #ASCO24 enhancing the art of cancer care and potentially transforming treatment approaches for patients... pharmaphorum.com/oncology/asco-โ€ฆ

Matt Simmons ๐Ÿ’Š (@matthewhsimmons) 's Twitter Profile Photo

The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosingโ€” Challenging the โ€œmore is betterโ€ dogma journals.sagepub.com/doi/full/10.11โ€ฆ

Matt Simmons ๐Ÿ’Š (@matthewhsimmons) 's Twitter Profile Photo

The latest performance data from the UKโ€™s MHRA reveal that clinical trial applications continue to be handled within the target statutory timescales - average of 27 days compared with the statutory timescales of 30 days) gov.uk/government/pubโ€ฆ

Matt Simmons ๐Ÿ’Š (@matthewhsimmons) 's Twitter Profile Photo

What else is needed in the near-term to change the trajectory of the past five years and increase Europeโ€™s share of global oncology trial sites ? #ESMO24

What else is needed in the near-term to change the trajectory of the past five years and increase Europeโ€™s share of global oncology trial sites ? #ESMO24
IQVIA Institute (@iqvia_institute) 's Twitter Profile Photo

๐Ÿ“Š Shifts in global clinical trial distribution: Europe's share declines across most segments, while China sees growth, except in biosimilars. More on these regional trends from our Rethinking Clinical Trial Country Prioritization report: bit.ly/3XE9hAQ. #ClinicalTrials

๐Ÿ“Š Shifts in global clinical trial distribution: Europe's share declines across most segments, while China sees growth, except in biosimilars. More on these regional trends from our Rethinking Clinical Trial Country Prioritization report: bit.ly/3XE9hAQ. #ClinicalTrials
Matt Simmons ๐Ÿ’Š (@matthewhsimmons) 's Twitter Profile Photo

Sequencing whole genome of newborns will be โ€˜transformationalโ€™ in earlier diagnosis and treatment of rare diseases... theguardian.com/society/2024/oโ€ฆ